{"id":"NCT03600376","sponsor":"Eagle Pharmaceuticals, Inc.","briefTitle":"Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS","officialTitle":"Phase 3, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-19","primaryCompletion":"2019-08-14","completion":"2019-08-14","firstPosted":"2018-07-26","resultsPosted":"2021-04-26","lastUpdate":"2021-05-19"},"enrollment":17,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Exertional Heat Stroke"],"interventions":[{"type":"DRUG","name":"Ryanodex and Standard of Care","otherNames":["Ryanodex and SOC"]},{"type":"OTHER","name":"Standard of Care","otherNames":["SOC"]}],"arms":[{"label":"Ryanodex and Standard of Care","type":"EXPERIMENTAL"},{"label":"Standard of Care only (SOC)","type":"OTHER"}],"summary":"A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) compared to current Standard of Care (SOC) for EHS.","primaryOutcome":{"measure":"Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS â‰¥ 13 [Time Frame: 90 Minutes Post-randomization]","timeFrame":"90 minutes post-randomization","effectByArm":[{"arm":"Ryanodex and Standard of Care","deltaMin":4,"sd":null},{"arm":"Standard of Care Only (SOC)","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["Saudi Arabia"]},"refs":{"pmids":["33848093"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":9},"commonTop":["Seizure","Diarrhoea","Nausea","Coma Scale Abnormal","Haemoglobin decreased"]}}